RhoGAM(R) Brand Hailed as One of the Top Achievements in 50 Years of Women's Health
RARITAN, N.J., Feb. 9 /PRNewswire/ -- RhoGAM(R) Brand, the original Rh immune globulin product, celebrates its 40th year in the marketplace helping Rh-negative women in the prevention of Hemolytic Disease of the Newborn (HDN). In 1968, a new mother at Holy Name Hospital in Teaneck, N.J., helped make history as the initial recipient of the world's first injectable treatment to prevent the disease -- an event that marked the launch of one of the most significant medical breakthroughs of the 20th century. Prior to the introduction of RhoGAM(R) Brand, nearly 10,000 babies died each year in the U.S. alone from HDN.(1)
"Today, this condition has been substantially reduced due to the safe and effective use of Rh immune globulin products, saving hundreds of thousands of newborns from crippling birth defects and possible death," said Ronald T. Burkman, MD, attending physician at Wesson Women's Group, Baystate Medical Center and Professor of Obstetrics and Gynecology,
HDN can develop when the Rh-negative blood of a pregnant woman comes in contact with the Rh-positive blood of her fetus. These Rh-negative women become sensitized and make antibodies that attack the blood of the Rh-positive fetus.(2) This reaction usually does not affect the first pregnancy, but once the mother has produced Rh antibodies, all future pregnancies are at risk.
"It is still important for women, as part of their prenatal care, to have a blood test and find out their blood type," continued Dr. Burkman.
About RhoGAM(R) Brand
Rh immune globulin products prevent the body from making antibodies that would destroy Rh-positive cells in future pregnancies and cause HDN to develop. RhoGAM(R) Br
|SOURCE Ortho-Clinical Diagnostics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved